FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination treatment for advanced breast cancer patients.

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and Roche's HER2 antibody, Perjeta (pertuzumab), to the widely used THP ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to ...